Objective: To describe a unique case of Gerstmann-Straüssler-Scheinker (GSS) disease caused by a novel prion protein (PRNP) gene mutation and associated with strongly positive voltagegated potassium channel (VGKC)-complex antibodies (Abs).
scanning of the body revealed no malignancy. An EEG showed nonspecific encephalopathic change. Repeat MRI was normal with no medial temporal lobe change.
Immune-mediated encephalitis was the presumed diagnosis. Prednisolone 60 mg daily was commenced. He received IV immunoglobulin at a dose of 2.0 g/kg. Attempted plasma exchange was not tolerated. He failed to respond despite 2 further courses of IV immunoglobulin at months 2 and 3 of admission. Mycophenolate mofetil was started after 4 months, but 5 months into his admission, he had minimal spontaneous activity, flat affect, and poor comprehension. He was immobile and experienced focal seizures, although not faciobrachial dystonic seizures, 6 which responded to anticonvulsant therapy. He had limb and trunk dystonia (antipsychotic agents had been used for behavioral management). Repeat paraneoplastic Abs and CT of the body were negative. Rituximab (1,000 mg) was administered in the fifth month of his admission, but there was no clinical improvement and persistently elevated VGKC-complex Abs (.2,000 pM). The patient continued to deteriorate and died 14 months after initial presentation.
RESULTS
Postmortem investigations. General postmortem examination revealed no evidence of systemic malignancy. The immediate cause of death was necrotizing bronchopneumonia. Macroscopic examination of the brain revealed no evidence of cerebral or cerebellar atrophy, and no focal abnormalities were identified. Histologic examination showed numerous multicentric amyloid plaques in the cerebral cortex, basal ganglia, thalamus, and cerebellum ( figure 1A) . Occasional plaques were also identified in the subcortical white matter of the cerebral hemispheres and cerebellum. Spongiform change was absent in the cerebral cortex and subcortical gray matter, and only patchy spongiform change was identified in the cerebellar molecular layer. Immunohistochemistry for prion protein (see Head et al. 7 for methodology) showed intense labeling of the amyloid plaques, and revealed occasional smaller deposits that were not apparent on routinely stained sections (figure 1B). Occasional small prion protein deposits (but no plaques) were present in the brainstem and in the substantia gelatinosa of the spinal cord, but not in spinal nerve roots and dorsal root ganglia. No prion protein deposition was observed in the heart, kidney, liver, lungs, pancreas, pituitary gland, prostate, and thyroid gland. Immunohistochemistry for the b-amyloid protein and a-synuclein was negative, while tau immunohistochemistry labeled only a few fine neuritic processes around the plaques in the cerebral cortex. No neurofibrillary tangles were identified, and there was no evidence of inflammation, immunoglobulin, or complement deposition in the brain. 8 Samples of fresh-frozen gray matter-enriched frontal and temporal cortex were homogenized, proteinase K digested, and analyzed by Western blotting, using the anti-PrP monoclonal Ab 3F4 as described previously. 7 The 2 brain regions gave qualitatively and quantitatively similar results. Those from frontal cortex are shown (figure 2). PrP was readily detectable before proteinase K digestion, including bands in the 20-to 40-kDa molecular mass range and a fainter low-molecular-mass band ( DNA was extracted from the frozen brain tissue, and full sequence analysis of the PRNP gene was performed as previously described. 7 The patient was heterozygous (MV) at codon 129 in the prion protein gene and had a silent A117A polymorphism that is not pathogenic. 9 The novel finding was a mutation at codon 84, P84S, a hitherto undescribed mutation in the PRNP gene.
DISCUSSION This patient had high-titer VGKCcomplex Abs and was treated for presumed Abmediated encephalitis. A number of atypical features should have raised doubts about this diagnosis; he had a relatively long prodrome with mild amnesia, wordfinding difficulties, visuospatial deficits, and a behavioral syndrome. The patient then progressed relentlessly with cognitive and neurologic decline, with seizures only as a late feature. MRI scanning revealed no medial temporal lobe changes. There was no treatment response to prolonged immunotherapies. No specific Ab to LGI1, CASPR2, or contactin2 could be detected, although the serum IgG bound to live neurons in culture, suggesting unidentified Ab(s) to cell surface antigen(s). Over the course of his illness, and regarding his rapid decline, there were clinical features consistent with prion disease; however, his MRI did not reveal signal change on diffusionweighted or fluid-attenuated inversion recovery sequences. CSF analysis was not performed because CSF findings in VGKC-complex Ab syndromes are usually either normal or nonspecific. 10, 11 Most patients with nonparaneoplastic VGKCcomplex Ab-associated encephalitis have a subacute or acute onset of symptoms characterized by disorientation, amnesia, temporal lobe seizures, and agitation; more than half have MRI changes of medial temporal lobe high signal on T2 or fluid-attenuated inversion recovery, an equal number have plasma hyponatremia at onset, and the majority respond to immunosuppression. Approximately 80% of patients are positive for LGI1 Abs and fewer for CASPR2. 2 Therefore, our patient differed in many respects from the classic description of VGKC-complex Ab-associated encephalitis.
The postmortem diagnosis of GSS disease was surprising. Our patient had no strong family history to indicate a genetic prion disease; the details of his mother's parkinsonism are unknown. GSS is a rare autosomal dominant inherited prion disease that classically presents with a slowly progressive spinocerebellar syndrome, lower limb areflexia, and late cognitive impairment. Classic ataxic onset GSS disease is associated with a P102L mutation in the prion protein gene, but some patients present with cognitive deficits reminiscent of Alzheimer disease and others with a CJD-like illness. 12 Patients with 6 octapeptide repeat insertion (OPRI) mutations are also clinically heterogeneous, but most present with a multifocal cortical dementia, often slowly progressive, with combinations of ataxia, parkinsonism, and pyramidal signs. 13 Patients with 5 OPRI mutations may present with CJD-like or Alzheimer-like syndromes. 9 Thus, while our patient did not clinically conform to a typical GSS disease presentation, the combination of cognitive and behavioral prodrome followed by more rapidly progressive dementia and neurologic decline is recognized within genetic prion disease, and the pathologic and biochemical findings in this case are characteristic of GSS disease.
The P84S mutation in the PRNP gene has not been reported previously in association with GSS disease, any other disease, or in normal populations, suggesting that it is highly likely to be a novel pathogenic mutation. [14] [15] [16] Furthermore, the functional effect of the P84S mutation is predicted to be "probably damaging." 17 In contrast, the A117A polymorphism is "silent" and not considered pathogenic. 9 The P84S mutation is located inside the N-terminal domain of the human prion protein, which is unstructured, nonessential for prion propagation, but is one of 2 high-affinity binding sites for divalent transition metals. 18 Altered metal-ion occupancy of prion protein has been found in sporadic CJD and may contribute to the diversity of the disease phenotype, but no comparable information is available for GSS disease. 19 There are no reported cases of strongly positive VGKC-complex Abs in patients with pathologically confirmed prion disease. However, 2 cases of autopsy-confirmed sporadic CJD have been reported with NMDA receptor Abs at relatively low titers. 20 Another patient with postmortem-confirmed CJD had both VGKC Abs at low titers (,400 pM) and glycine receptor Abs. 21 In 49 confirmed CJD cases, no LGI1 or CASPR2 Abs were detected in CSF although lack of serum testing limits the comparison with this study. 22 High titers of VGKC-complex Abs are regarded as specific for immune-mediated disease with only one of 150 neurologic control patients positive for VGKC-complex Abs. 23 However, a recent study suggests they may be more frequent. 24 The VGKC-complex Abs in our patient may have reflected a coincidental autoimmune process, but the lack of a treatment effect despite high-dose multimodal immunotherapy would argue against this. These Abs may be induced by degenerating neurons but further studies are needed to determine the frequency of VGKCcomplex Abs in neurodegenerative disease.
Thus, this case sounds a note of caution. Although some VGKC-complex Ab-positive patients without LGI1 or CASPR2 Abs do have the hallmarks of limbic encephalitis, 25 a failure to respond to aggressive immunotherapy should question an immune-mediated illness. As more patients are tested for these Abs, there are likely to be further cases of this kind. The presence of a strongly positive VGKC-complex Ab does not preclude the diagnosis of prion disease.
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